CD38 and Miyoshi myopathy: This prespecified subgroup analysis of ICARIA-MM—the first randomized phase 3 study to demonstrate a significant survival benefit of an anti-CD38 therapy (Isa) plus Pd versus Pd in heavily pretreated patients with RRMM [22]—shows that Isa-Pd is also efficacious with a manageable safety profile in patients with RI.